MEIP — MEI Pharma Cashflow Statement
0.000.00%
Last trade - 00:00- $13.99m
- -$9.75m
- $65.30m
- 46
- 45
- 42
- 40
Annual cashflow statement for MEI Pharma, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K/A | 10-K/A | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -47.2 | -41.3 | -54.5 | -31.8 | 17.8 |
| Depreciation | |||||
| Non-Cash Items | 29.9 | -7.88 | -11.5 | 3.92 | 15.6 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 51.4 | 16.9 | 16.9 | -24.9 | -84.3 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 34.3 | -32 | -48.7 | -52.5 | -50.5 |
| Capital Expenditures | -0.894 | -0.708 | -0.479 | -0.035 | -0.007 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -105 | 25.4 | 7.37 | 53.7 | 49.1 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -106 | 24.7 | 6.89 | 53.7 | 49.1 |
| Financing Cash Flow Items | 5.27 | — | -3.85 | -0.04 | -0.208 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 74.8 | 3.47 | 49.1 | -0.04 | -11.9 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 2.74 | -3.79 | 7.2 | 1.17 | -13.2 |